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Perioperative hyperglycemia exacerbates the cytokine, inflammatory, 
and oxidative stress response. It is associated with increased rates of 
postoperative infectious complications (POICs), such as surgical site infection 
(SSI), in patients with diabetes after abdominal surgery1,2, including 
pancreaticoduodenectomy (PD).3 In addition, increased perioperative glycemic 
variability (GV) in combined with hyperglycemia is more detrimental than 
hyperglycemia alone,4,5 which may result in a high risk of POICs. 
Artificial pancreas (AP) consists of a continuous glucose monitor and an 
insulin pump6, designed to automatically adjust blood glucose values in real 
time, making tight glycemic control (TGC) possible with reduced GV.7 Therefore, 
TGC using AP (TGC-AP) can prevent not only perioperative hyperglycemia, but 
also hypoglycemia, despite a large amount of insulin.8 Although the anti-
inflammatory mechanism has yet to be established, TGC-AP improves the rate 
of POICs after pancreatic surgery.9  
Insulin has been considered a key metabolic hormone with effects on 
glucose and lipid metabolism. In addition, its anti-inflammatory effects in 
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patients with traumatic hyperglycemia are rapid and activated within 2 
hours.10,11 
Adiponectin, an adipocyte-derived secretory protein that plays a key 
role in glucose metabolism, exhibits anti-inflammatory properties and inverse 
associations between adiponectin and interleukin (IL)-6 levels.12 The relative 
decrease in preoperative adiponectin levels, as well as in the adiponectin ratio 
(postoperative adiponectin levels/preoperative adiponectin levels), is an 
independent risk factor for POICs after gastrointestinal surgery.13,14 These 
findings suggest that perioperative adiponectin levels contribute to the 
development of the inflammatory response following abdominal surgery. 
In this study, we report the results of a single-center, prospective, and 
non-randomized clinical trial of perioperative TGC-AP in patients with impaired 
glucose tolerance (IGT) following PD. We hypothesized that TGC-AP, using a 
large amount of insulin, would reduce the rate of POICs, at least in part, by 
modulating inflammatory mediators, including adiponectin, after surgery. 
 
Materials and methods 
The study conformed to the Clinical Research Guidelines of Shiga 
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University of Medical Science and was approved by the institutional ethics 
committee (approval number 27-47) followed by pre-registration in the UMIN 
Clinical Trials Registry (UMIN ID 000023460). The trial was performed in 
accordance with the principles of the Declaration of Helsinki.  
Patients 
We recruited patients who underwent PD for a biliary pancreatic tumor at 
Shiga University of Medical Science Hospital between April 2016 and March 2018. 
Inclusion criteria included age of 20 years or older and inpatients with diabetes 
(hemoglobin A1c ≥6.5%, fasting plasma glucose level ≥126 mg/dL, or requiring 
hypoglycemic agents) or “borderline” diabetes according to a 75-g oral glucose 
tolerance test (OGTT), defined as a plasma glucose concentration of 140-199 
mg/dL 2 h after the oral intake of a 75-g glucose load.15 Patients with severe 
respiratory disease or who underwent dialysis were excluded. All patients 
provided written informed consent prior to enrollment.  
Trial design 
This was a prospective, non-randomized, single-center study with a 24-
hour intervention and a 30-day follow-up. The enrolled patients were divided into 
two groups according to the period of time to assess the value of AP for POICs. 
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In the first-half period, conventional glycemic control was performed (control 
group). Then, in the last-half period, TGC-AP was performed (AP group) (Figure 
1). There were no changes in perioperative management or surgical members 
throughout this study period. 
Trial procedures 
Glycemic monitoring was typically performed just after the start of surgery 
and was continued for 24 h (perioperative period) using AP, followed by sliding-
scale insulin administration for the control of elevated glucose for patients in both 
groups, without the use of strict insulin regimens to prevent hyperglycemia 
greater than 180 mg/dL. The AP uses a dual lumen catheter blood sampling 
technique every 2 s and can automatically infuse insulin and /or glucose to adjust 
blood glucose levels. The perioperative period was divided into two parts: 
intraoperative (start to the end of surgery) and postoperative (immediately after 
surgery up to the following 24 hours); blood glucose control was performed in 
each period. 
Tight glycemic control: The AP group continuously maintained their target glucose 
range of 80 to 110 mg/dL during the perioperative period using AP7 (STG-55 
system; Nikkiso Inc., Tokyo, Japan). The AP system, a closed-loop glycemic 
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control system7, is a reliable and accurate device to measure blood glucose levels, 
compared to the ABL800 FLEX machine (Radiometer Medical ApS, Denmark) 
recommended by the National Committee for Clinical Laboratory.16 
Conventional glycemic control: The control group only continuous monitoring of 
blood glucose by AP and routine checking at 2-h intervals by nursing staff to 
remain within the target blood glucose range. Insulin infusion was performed 
when the blood glucose level exceeded 180 mg/dL17 during the perioperative 
period.  
Primary and secondary outcomes 
The primary outcome was the POIC rate during the 30-day postoperative 
observation period. POICs in this study were defined as the occurrence of 1 or 
more reports of incisional and organ/space SSI18 and remote infections within the 
first 30 days of surgery. All patients were checked daily for signs of infection, and 
results were interpreted by an investigator blinded to the treatment assignment. 
Diagnosis of infection was confirmed bacteriologically by a positive culture. 
According to the Centers for Disease Control and Prevention19, the criteria for all 
SSIs were at least one of the following: (i) purulent discharge with or without 
laboratory confirmation from the superficial incision; (ii) organisms isolated from 
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an aseptically obtained culture of fluid or tissue from the superficial incision; (iii) 
at least one of the indicated signs or symptoms of infection (pain or tenderness, 
localized swelling, redness, or heat from the superficial incision deliberately made 
by surgeon, unless the incision is culture-negative); and (iv) a diagnosis of 
superficial SSI by the surgeon or attending physician. Secondary outcomes were 
perioperative factors (duration of surgery, estimated blood loss, blood transfusion, 
and length of postoperative hospital stay), and hematological examinations for 
infection. Insulin secretion was evaluated using the serum level in the C-peptide 
response, as an indicator of endogenous insulin production, and insulin 
resistance was evaluated using the homeostasis model assessment of insulin 
resistance (HOMA-IR), which was calculated using the following formula: fasting 
plasma glucose (G0) x fasting insulin (I0) / 405. We used glucose data collected 
throughout the trial period (intraoperative and postoperative period) and analyzed 
it for GV according to the coefficient of variation (CV; standard deviation (SD) / 
mean blood glucose). Hypoglycemic events (blood glucose level of < 70 mg/dL), 
as well as the total amount of insulin required for glycemic control throughout the 




Blood samples were used to measure plasma IL-6 and IL-10 levels using 
a commercial enzyme-linked immunosorbent assay (R&D Systems Inc., 
Minneapolis, MN, USA), and adiponectin levels were measured using a latex 
particle-enhanced turbidimetric assay (Otsuka Pharmaceutical Co. Ltd., Tokyo, 
Japan), as described previously20 before surgery and on the first postoperative 
day (POD). In addition, the adiponectin ratio was calculated as the adiponectin 
value on POD1 divided by the preoperative adiponectin value.13  
Statistical analysis  
Sample size calculation was based on the effectiveness of TGC-AP in 
patients for whom PD was indicated. Anticipating anti-inflammatory effectiveness 
in TGC-AP (30-day POIC rate 50% vs. 10%) based on previous studies21,22, 
approximately 16 patients per group would be needed in order to detect any 
significant effects of TGC-AP, with a one-sided alpha level of less than 0.05 and 
a beta level of 0.2. Continuous variables were presented as SD without skewed 
distribution and as medians (interquartile ranges) with skewed distribution. 
Dichotomous variables were presented as number and percentage. Differences 
among the study groups were determined using the chi-square test (two-tailed) 
or Fisher’s exact test (two-tailed) for comparison of proportions, by the Wilcoxon 
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rank sum test for non-normally distributed numerical data and by Student’s t-test 
for normally distributed numerical data. A two-sided P-value of less than 0.05 was 
considered statistically significant. Calculations were performed with the 




Of the 52 consecutive patients who underwent PD were assessed for 
eligibility by glucose tolerance before surgery, 32 patients were divided into two 
groups: TGC (AP group; n=16) or conventional glycemic control (control group; 
n=16) (Figure 1). We withdrew one patient in each group after allocation because 
the procedure was changed from PD to total pancreatectomy. Another patient in 
the AP group was excluded due to problems with the use of AP, resulting in 
inadequate TGC. Therefore, the final 29 patients eligible for this study were 
subjected to the intervention. The baseline and operative characteristics of the 
patients were similar, and there was no significant difference between the two 
groups (Table 1). 
Alteration of perioperative blood glucose level 
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The mean blood glucose levels were maintained close to the target range 
in each group during the perioperative period without hypoglycemia (<70mg/dL) 
(Figure 2), but the mean GV was significantly different between the control and 
AP groups during the postoperative period (19.7±2.4% vs. 15.0±3.6%; P=0.004) 
and perioperative period (16.4±5.9% vs. 13.5±3.5%; P=0.038) (Table 2). 
Postoperative clinical outcomes 
There was a significant difference in the POIC rate between the control 
and AP groups (73.3% vs. 28.6%; P=0.027), but the length of postoperative stay 
was not markedly different (32 vs. 17 days; P=0.065) (Table 3). A total of forty-
two microorganisms were isolated, the most common being Enterococcus 
species, Staphylococcus species, and Enterobacter species (Table 4). Total 
insulin requirements during the first 24 hours from the start of the surgery were 
significantly different in the two groups (control 10.2±16.2 vs AP 27.0±13.4 U; 
P=0.002).  
Postoperative systemic inflammatory changes 
The preoperative values of the white blood cell count and C-reactive 
protein, IL-6, IL-10, and adiponectin levels were not significantly different between 
the control and AP groups. Only the IL-6 level on POD1 (98.3±89.1 vs. 26.3±33.8 
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pg/mL; P=0.036) and the adiponectin ratio (0.6±0.3 vs. 0.8±0.2; P=0.021) were 
significantly different in the two groups (Table 5). 
 
Discussion 
In this trial involving patients with IGT, those who received TGC with a 
fully automated, closed-loop system had significantly better infection control than 
those who received conventional glycemic control. The GV, serum IL-6 level on 
POD1, and perioperative adiponectin ratio were significantly different in the two 
groups after PD. TGC-AP may exert an anti-inflammatory effect on patients by 
improving the GV as well as the systemic inflammatory response that originates 
from adipose tissue inflammation after surgery. 
The incidence of POICs was relatively higher (73%) than that in previous 
reports, although recent studies reported a POIC rate of approximately 70% in 
some cases.23,24 The important point is that approximately 30% of the patients 
enrolled in this study were preoperatively diagnosed with borderline diabetes 
using the OGTT test. In general, patients with borderline diabetes are not 
included in the “diabetes” group, because it is difficult to detect without a glucose 
tolerance test. Patients with borderline diabetes have higher perioperative 
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morbidity rate than those without diabetes and those with known diabetes.25,26 
Consequently, patients with IGT, including those with borderline diabetes, were 
at risk of POICs, as reported previously.1,2 These findings suggest that borderline 
diabetes may contribute to a further increase in the POIC rate and may also be 
an explanation for the different results on the POIC rate. 
The current guidelines for patients undergoing surgery recommend 
perioperative TGC27, even though its application demonstrates contradicting 
results. Unlike our study, some previous studies showed no benefit of TGC in 
critically ill patients who had undergone cardiac surgery.28,29 More specifically, 
TGC was controlled only after surgery and not during the perioperative period, as 
was done in this study, which may be one of the reasons for its contradicting 
results. Several results, similar to those of this study, have been reported in a 
study of performing TGC during the perioperative period of cardiac surgery.30,31 
Although there is no consensus target range currently, the Society of 
Thoracic Surgeons Practice Guidelines suggest that a glucose level >180 mg/dL 
after surgery should be treated with intravenous insulin and maintained at <180 
mg/dl.17 The control group in this study conformed to the target range with 
reference to this guideline and blood glucose was controlled via blood sampling 
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every 2 hours. 
Cytokines such as IL-6 and IL-10 are thought to play a pivotal role in the 
pathogenesis of surgical trauma, and macrophages are likely the source of most 
of cytokine production in several tissues, including adipose tissue.32 Adipose 
tissue inflammation, which is known to play an important role in the pathology of 
chronic inflammation, is also involved in acute inflammation during the 
perioperative period.33,34 Considering the fact that intraperitoneal adipose tissue 
is directly traumatized in most surgical procedures during abdominal surgery, it is 
likely that macrophages recruited in adipose tissue contribute to acute 
inflammatory reactions after PD. 
The ability of insulin to attenuate the systemic inflammatory response by 
decreasing the pro-inflammatory cascade while increasing the anti-inflammatory 
cascade has been well established.35,36 In addition, insulin has been reported to 
decrease pro-inflammatory proteins, including IL-6, within macrophages.37 The 
present results, which demonstrated that the total insulin requirements were 
significantly higher in the AP group than in the control group, indicating its anti-
inflammatory effect, occurred, at least in part, due to exogenous insulin itself. 
Considering the fact that adipose tissue is one of the target organs of insulin, their 
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interrelationship may be important in the perioperative period. 
Adiponectin, one of the adipocytokines secreted primarily from adipose 
tissue, has been identified as having anti-inflammatory properties that inhibit 
macrophage function.38 Recently, we reported that the adiponectin ratio is the 
earliest postoperative measure available that reflects the perioperative 
inflammatory factor.19 In this study, the adiponectin ratio was markedly lower in 
the control group than in the AP group (P=0.021), reflecting the compensatory 
nature of adiponectin to the inflammatory response seen with surgery during the 
perioperative period and further supporting the association of perioperative 
adiponectin levels with anti-inflammatory action after PD.  
There is a possibility that the GV, rather than the absolute value of blood 
glucose levels, is responsible for the observed beneficial effect after PD. In this 
study, postoperative GV in the control group was significantly higher because the 
mean glucose level increased gradually after surgery. Therefore, our findings 
suggest that high postoperative GV is associated with the development of an 
inflammatory response to surgery.  
This study must be interpreted in the context of its limitations and 
additional research is needed in order to provide more definitive answers on the 
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potential benefit of TGC during surgery. Future research should (1) address the 
differences between diabetic and non-diabetic patients with respect to TGC and 
outcomes; (2) evaluate the proper blood glucose range to confer the optimal 
benefit during the perioperative period; (3) include larger, randomized, 
multicentered collaborative studies; and (4) examine the trends of inflammatory 
mediators after surgery in more detail and for a longer period.  
Conclusions 
We found that TGC-AP by intravenous insulin treatment had beneficial 
effects on POICs in patients with IGT who underwent PD. Adiponectin may be 
involved in an anti-inflammatory response to abdominal surgery and in 
conjunction with exogenous insulin using AP, thereby preventing postoperative 
infectious complications. 
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Baseline and operative characteristics of 29 patients who underwent 
pancreatoduodenectomy 
Baseline characteristic Control Artificial 
pancreas 
P-value 
Age (years) 69 (66-76) 72 (58-76)   0.930 
Sex: male/female 10/5 11/3 0.681 
Diagnosis:  
Pancreatic cancer/others 
8/7 7/7 0.710 
Body mass index  21.3 (19.9-23.7) 23.0 (21.3-24.0) 0.198 
Glucose tolerance: 
borderline/diabetes 
4/11 4/10 0.763 
C-peptide response (ng/mL) 1.27 (0.91) 1.28 (0.64) 0.980 
HOMA-IR 1.25 (0.48-1.78) 1.09 (0.98-1.34) 0.898 
Blood chemistry    
Hemoglobin (g/dl) 12.2 (1.4) 12.9 (1.8) 0.287 
Total protein (g/dl) 6.3 (0.6) 6.7 (0.7) 0.171 
Albumin (g/dl)  3.5 (0.4) 3.8 (0.5) 0.138 
Amylase (units/L) 97 (80) 89 (62) 0.763 
Cholesterol (mg/dL) 184 (34) 189 (49) 0.814 
Triglycerides (mg/dL) 108 (43) 95 (33) 0.447 
Fasting blood glucose (mg/dL) 110 (21) 102 (16) 0.375 
Hemoglobin A1C (%) 6.7 (0.7) 6.9 (1.0) 0.690 
Operative characteristic    
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Duration of surgery 
(minutes) 
481 (104) 478 (125) 0.570 
Estimated blood loss (g) 752 (566-1,088) 739 (602-1,108) 0.880 
Blood transfusion: +/- 4/11 2/12 0.651 
Pancreatic texture 
hard/soft 
7/8 8/6 0.715 
MPD (mm) 2.5 (2.0-3.8) 3.8 (2.3-5.0) 0.230 
HOMA-IR, homeostasis model of assessment of insulin resistance; MPD, main 
pancreatic duct; SD, standard deviation. 
Data are presented as mean (SD) for continuous variables without skewed 






Table 2  
Perioperative glucose values of 29 patients who underwent 
pancreatoduodenectomy 
 Control Artificial 
pancreas 
P-value 
Intraoperative period    
Mean blood glucose 
(mg/dL) 
113 (105-116) 99 (97-100) 0.001 
GV: SD/mean blood glucose 
(%) 
13.9 (7.0) 11.1 (1.7) 0.429 
Postoperative period    
Mean blood glucose 
(mg/dL) 
136 (127-149) 112 (108-114) <0.001 
GV: SD/mean blood glucose 
(%) 
19.7 (2.4) 15.0 (3.6) 0.004 
Perioperative period    
Mean blood glucose 
(mg/dL) 
126 (114-145) 108 (99-113) < 0.001 
GV: SD/mean blood glucose 
(%) 
16.4 (5.9) 13.5 (3.5) 0.038 
GV, glycemic variability; SD, standard deviation. 
Data are presented as mean (SD) for continuous variables without skewed 






Table 3  
Postoperative outcomes 




Total, n (%) 
11 (73.3) 4 (28.6) 0.027 
Surgical site infections (n) 10 4 0.066 
Superficial/deep incisional 1 1  
Organ/space  9 3  
Postoperative pancreatic fistula (n) 6 3 0.497 
Grade B 6 3  
Grade C 0 0  
Remote infection (n) 9 3 0.060 
Bacteremia 3 2  
Pneumonia 3 1  
Cholangitis 1 0  
Enteritis  2 0  
Urinary tract infection 0 0  
Total insulin requirement (U) 






Postoperative stay (days) 32 (28-45) 17 (13-33) 0.065 
Data are presented as mean (standard deviation) for continuous variables  
without skewed distribution and median (interquartile range) for continuous  
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Table 4  




Positive cultures 18  4  
Monomicrobial 3  1  
Polymicrobial 8  3  
Isolated microorganisms   
Enterococcus species 5  0  
Staphylococcus species 4  1  
Enterobacter species 4  1  
Streptococcus species 3  1  
Candida species 3  1  
Neisseria species 3  0  
Pseudomonas species 0  2  
Klebsiella species 1  1  
Corynebacterium species 2  0  
Aeromonas species 2  0  
Morganella species 2  0  
Propionibacterium species 1  0  
Citrobacter species 0  1  
Serratia species 1  0  
Stomatococcus species 1  0  
Stenotrophomonas species 1  0  
Clostridium species 1  0  




Table 5  
Perioperative changes in WBC count and CRP, IL-6, IL-10, and adiponectin 
levels 
Parameter Control Artificial pancreas P-value 
WBC    
Pre 5,460 (1,544) 5,700 (1,268) 0.640 
POD1 9,100 (3,025) 9,679 (3,181) 0.390 
CRP, mg/mL    
Pre 1.0 (1.9) 0.6 (1.2) 0.504 
POD1 9.2 (2.9) 8.9 (2.9) 0.832 
IL-6, pg/mL    
Pre B.D.V. B.D.V.  
POD1 98.3 (89.1) 26.3 (33.8) 0.036 
IL-10, pg/mL    
Pre 2.6 (5.2) 5.7 (10.7) 0.477 
POD1 4.3 (3.9) 8.8 (11.5) 0.296 
Adiponectin, mg/dL    
Pre 7.7 (3.7) 4.0 (2.1) 0.050 
POD1 3.8 (2.1) 2.9 (1.1) 0.341 
Ratio 0.6 (0.3) 0.8 (0.2) 0.021 
WBC, white blood cell; B.D.V., below detection value. CRP, C-reactive protein; IL, 
interleukin; POD, postoperative day; B.D.V., below detection value. 





Figure 1. Study flow chart 
Figure 2. Intraoperative and postoperative mean blood glucose levels in the 
control and artificial pancreas groups during the first 24 hours following PD 
   # p<0.01, * p<0.05 compared with Artificial Pancreas 
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